TP53 and acute myeloid leukemia: In this study from the ALWP of the EBMT, we demonstrate that patients with TP53‐mutated AML who have undergone an allo‐SCT in CR1 had an inferior OS to those without a mutation in TP53, regardless of the presence of concomitant high risk cytogenetic features, such as loss of chromosome 5 or 7.